STOCK TITAN

[Form 4] VOLITIONRX LTD Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4

Gael Forterre, Chief Commercial Officer and reporting person for VolitionRx Ltd (VNRX), reported a transaction dated 09/28/2025 that reduced his direct common stock holdings by 5,503 shares at a price of $0.605 per share. The filing explains these 5,503 shares were retained by the issuer to satisfy tax withholding obligations upon settlement of 13,725 restricted stock units; no shares were sold by Mr. Forterre or VolitionRx. After the reported transaction he beneficially owns 160,924 shares directly, plus 5,000 shares held by his spouse and 32,500 shares managed by Armorica Partners, LLC, for which he is the managing director and sole shareholder.

Gael Forterre, Chief Commercial Officer e persona informante per VolitionRx Ltd (VNRX), ha comunicato una operazione datata 09/28/2025 che ha ridotto le sue partecipazioni dirette in azioni ordinarie di 5,503 azioni al prezzo di $0.605 per azione. Il deposito spiega che queste 5,503 azioni sono state trattenute dall'emittente per soddisfare gli obblighi di ritenuta fiscale al settlement di 13,725 restricted stock units; nessuna azione è stata venduta dal signor Forterre o da VolitionRx. Dopo l'operazione riportata, detiene beneficiamente 160,924 azioni direttamente, oltre a 5,000 azioni detenute dal coniuge e 32,500 azioni gestite da Armorica Partners, LLC, di cui è managing director e unico azionista.

Gael Forterre, Director Comercial y persona informante para VolitionRx Ltd (VNRX), informó una operación con fecha 28/09/2025 que redujo sus participaciones directas de acciones comunes en 5,503 acciones a un precio de $0.605 por acción. El archivo explica que estas 5,503 acciones fueron retenidas por el emisor para satisfacer las obligaciones de retención fiscal al liquidarse 13,725 units de acciones restringidas; ninguna acción fue vendida por el Sr. Forterre ni por VolitionRx. Después de la operación reportada posee, de manera beneficiosa, 160,924 acciones directamente, además de 5,000 acciones en poder de su cónyuge y 32,500 acciones gestionadas por Armorica Partners, LLC, para las cuales él es director gerente y único accionista.

Gael Forterre는 VolitionRx Ltd (VNRX)의 최고 상무책임자(Chief Commercial Officer) 겸 보고자이며, 09/28/2025로 기재된 거래가 그의 직접 보통주 보유를 5,503주 감소시키고 주당 $0.605의 가격으로 체결되었다고 보고했습니다. 제출 문서는 이 5,503주13,725 restricted stock units의 결제 시점에 세금 원천징수 의무를 충족하기 위해 발행사가 보유한 것이라고 설명합니다; Forterre씨나 VolitionRx가 주식을 매도한 것은 아닙니다. 보고된 거래 이후 그는 직접 보유 주식 160,924주를 보유하며, 배우자가 보유한 5,000주와 Armorica Partners, LLC가 관리하는 32,500주의 주식도 보유하는데, 이는 그가 관리 이사이자 유일 주주인 회사입니다.

Gael Forterre, Chief Commercial Officer et personne mandatée pour VolitionRx Ltd (VNRX), a signalé une opération datée du 28/09/2025 qui a réduit ses détentions directes d’actions ordinaires de 5 503 actions au prix de $0,605 par action. Le dépôt explique que ces 5 503 actions ont été retenues par l’émetteur pour satisfaire les obligations de retenue à la source lors du règlement de 13 725 unités d’actions restreintes; aucune action n’a été vendue par M. Forterre ni par VolitionRx. Après l’opération signalée, il détient avantageusement 160 924 actions directement, plus 5 000 actions détenues par son conjoint et 32 500 actions gérées par Armorica Partners, LLC, pour lesquelles il est directeur général et seul actionnaire.

Gael Forterre, Chief Commercial Officer und meldende Person für VolitionRx Ltd (VNRX), meldete eine Transaktion vom 28.09.2025, die seine direkten Stammaktienbestände um 5.503 Aktien zu einem Kurs von 0,605 USD pro Aktie verringerte. Die Einreichung erklärt, dass diese 5.503 Aktien vom Emittenten gehalten wurden, um die Steuerabzugsverpflichtungen bei der Abwicklung von 13.725 Restricted Stock Units zu erfüllen; keine Aktien wurden von Herrn Forterre oder VolitionRx verkauft. Nach der gemeldeten Transaktion besitzt er weiterhin direkt 160.924 Aktien, außerdem 5.000 Aktien, die von seinem Ehepartner gehalten werden, und 32.500 Aktien, die von Armorica Partners, LLC verwaltet werden, wofür er Geschäftsführer und Alleinaktionär ist.

Gael Forterre، Chief Commercial Officer والشخص المبلّغ باسم VolitionRx Ltd (VNRX)، أبلغ عن معاملة بتاريخ 28/09/2025 التي خفّضت حصته من الأسهم العادية المباشرة بمقدار 5,503 أسهم بسعر $0.605 للسهم. يوضح الملف أن هذه 5,503 أسهم قد احتُجزت من قبل المصدر لتلبية التزامات حجز الضرائب عند تسوية 13,725 وحدة أسهم مقيدة؛ لم يتم بيع أي أسهم من قبل السيد فورتير أو VolitionRx. بعد المعاملة المبلّغ عنها، يمتلك بشكل مفيد 160,924 سهماً بشكل مباشر، إضافة إلى 5,000 سهم يملكها زوجته و32,500 سهم تديرها Armorica Partners, LLC، التي يشغل فيها منصب المدير التنفيذي والمالك الوحيد.

Gael Forterre,VolitionRx Ltd(VNRX)的首席商务官及披露人,报告了一笔日期为 2025年9月28日 的交易,该交易将其直接普通股持有量减少了 5,503 股,每股价格为 $0.605。文件解释说这 5,503 股 是由发行人保留,以在结算 13,725 份受限股票单位 时履行税收代扣义务;Forterre先生或 VolitionRx 未出售任何股票。 在所述交易后,他直接持有的受益性股票为 160,924 股,此外还包括由其配偶持有的 5,000 股 和由 Armorica Partners, LLC 管理的 32,500 股,他为其管理董事兼唯一股东。

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Routine tax-withholding share retention reduced direct holdings; no open-market sale or new investment signaled.

The transaction code F indicates shares were withheld for tax obligations on RSU settlement rather than sold in the market, which mitigates downward price pressure from insider disposition. The filing quantifies the RSU settlement (13,725 RSUs) and the withheld amount (5,503 shares), and confirms continuing material ownership by the reporting person with 160,924 direct shares plus indirect positions. This is a routine insider administrative action with limited market impact.

TL;DR: Disclosure is complete for this event and clarifies indirect ownership links to Armorica Partners.

The Form 4 clearly discloses the nature of indirect holdings and Mr. Forterre's role with Armorica Partners, including a disclaimer of beneficial ownership except for pecuniary interest, which aligns with standard governance disclosure practices. The record shows compliance with Section 16 reporting timelines and transparent explanation of the withholding mechanism used to satisfy taxes on equity compensation.

Gael Forterre, Chief Commercial Officer e persona informante per VolitionRx Ltd (VNRX), ha comunicato una operazione datata 09/28/2025 che ha ridotto le sue partecipazioni dirette in azioni ordinarie di 5,503 azioni al prezzo di $0.605 per azione. Il deposito spiega che queste 5,503 azioni sono state trattenute dall'emittente per soddisfare gli obblighi di ritenuta fiscale al settlement di 13,725 restricted stock units; nessuna azione è stata venduta dal signor Forterre o da VolitionRx. Dopo l'operazione riportata, detiene beneficiamente 160,924 azioni direttamente, oltre a 5,000 azioni detenute dal coniuge e 32,500 azioni gestite da Armorica Partners, LLC, di cui è managing director e unico azionista.

Gael Forterre, Director Comercial y persona informante para VolitionRx Ltd (VNRX), informó una operación con fecha 28/09/2025 que redujo sus participaciones directas de acciones comunes en 5,503 acciones a un precio de $0.605 por acción. El archivo explica que estas 5,503 acciones fueron retenidas por el emisor para satisfacer las obligaciones de retención fiscal al liquidarse 13,725 units de acciones restringidas; ninguna acción fue vendida por el Sr. Forterre ni por VolitionRx. Después de la operación reportada posee, de manera beneficiosa, 160,924 acciones directamente, además de 5,000 acciones en poder de su cónyuge y 32,500 acciones gestionadas por Armorica Partners, LLC, para las cuales él es director gerente y único accionista.

Gael Forterre는 VolitionRx Ltd (VNRX)의 최고 상무책임자(Chief Commercial Officer) 겸 보고자이며, 09/28/2025로 기재된 거래가 그의 직접 보통주 보유를 5,503주 감소시키고 주당 $0.605의 가격으로 체결되었다고 보고했습니다. 제출 문서는 이 5,503주13,725 restricted stock units의 결제 시점에 세금 원천징수 의무를 충족하기 위해 발행사가 보유한 것이라고 설명합니다; Forterre씨나 VolitionRx가 주식을 매도한 것은 아닙니다. 보고된 거래 이후 그는 직접 보유 주식 160,924주를 보유하며, 배우자가 보유한 5,000주와 Armorica Partners, LLC가 관리하는 32,500주의 주식도 보유하는데, 이는 그가 관리 이사이자 유일 주주인 회사입니다.

Gael Forterre, Chief Commercial Officer et personne mandatée pour VolitionRx Ltd (VNRX), a signalé une opération datée du 28/09/2025 qui a réduit ses détentions directes d’actions ordinaires de 5 503 actions au prix de $0,605 par action. Le dépôt explique que ces 5 503 actions ont été retenues par l’émetteur pour satisfaire les obligations de retenue à la source lors du règlement de 13 725 unités d’actions restreintes; aucune action n’a été vendue par M. Forterre ni par VolitionRx. Après l’opération signalée, il détient avantageusement 160 924 actions directement, plus 5 000 actions détenues par son conjoint et 32 500 actions gérées par Armorica Partners, LLC, pour lesquelles il est directeur général et seul actionnaire.

Gael Forterre, Chief Commercial Officer und meldende Person für VolitionRx Ltd (VNRX), meldete eine Transaktion vom 28.09.2025, die seine direkten Stammaktienbestände um 5.503 Aktien zu einem Kurs von 0,605 USD pro Aktie verringerte. Die Einreichung erklärt, dass diese 5.503 Aktien vom Emittenten gehalten wurden, um die Steuerabzugsverpflichtungen bei der Abwicklung von 13.725 Restricted Stock Units zu erfüllen; keine Aktien wurden von Herrn Forterre oder VolitionRx verkauft. Nach der gemeldeten Transaktion besitzt er weiterhin direkt 160.924 Aktien, außerdem 5.000 Aktien, die von seinem Ehepartner gehalten werden, und 32.500 Aktien, die von Armorica Partners, LLC verwaltet werden, wofür er Geschäftsführer und Alleinaktionär ist.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Forterre Gael

(Last) (First) (Middle)
1489 WEST WARM SPRINGS ROAD
SUITE 110

(Street)
HENDERSON NV 89014

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
VOLITIONRX LTD [ VNRX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Commercial Officer
3. Date of Earliest Transaction (Month/Day/Year)
09/28/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 09/28/2025 F 5,503(1) D $0.605 160,924 D
Common Stock 5,000 I By Spouse
Common Stock 32,500 I By Armorica Partners, LLC(2)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 13,725 restricted stock units. No shares were sold by the reporting person or VolitionRx in such transaction.
2. These shares of common stock are managed by Armorica Partners, LLC (formerly Armori Capital Management, LLC) ("Armorica Partners"). Mr. Forterre is the managing director and sole shareholder of Armorica Partners and has voting and dispositive control over the shares held by Armorica Partners. Mr. Forterre disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
Remarks:
/s/ Gael Forterre 09/30/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Volitionrx

NYSE:VNRX

VNRX Rankings

VNRX Latest News

VNRX Latest SEC Filings

VNRX Stock Data

66.94M
86.70M
17.84%
22.29%
0.28%
Medical Devices
In Vitro & in Vivo Diagnostic Substances
Link
United States
HENDERSON